Mesoblast (MESO) Beginning Cash Balance (2016 - 2025)
Mesoblast (MESO) posted Beginning Cash Balance of -$25.1 million for Q4 2022, down 141.45% sequentially from $60.4 million in Q3 2022.
Mesoblast (MESO) Beginning Cash Balance (2016 - 2025) Analysis & Trends
Mesoblast has reported Beginning Cash Balance for 7 years, with the latest figure at -$25.1 million in Q4 2022.
- Quarterly Beginning Cash Balance changed N/A year-over-year to -$25.1 million in Q4 2022, while the trailing twelve-month figure through Mar 2023 was $35.4 million (changed N/A YoY) and the FY2022 annual result came in at $136.9 million, up 5.84% from the prior year.
- Beginning Cash Balance fell to -$25.1 million in Q4 2022 per MESO's latest filing, from $60.4 million in the prior quarter.
- Over five years, Beginning Cash Balance peaked at $136.9 million in Q3 2021 and troughed at -$25.1 million in Q4 2022.
- A 5-year average of $49.5 million and a median of $44.1 million in 2018 frame the typical range for Beginning Cash Balance.
- The sharpest annual moves came in 2021 and 2022: Beginning Cash Balance surged 523.09% in 2021, then sank 55.84% in 2022.
- Over 5 years, Beginning Cash Balance stood at $37.8 million in 2018, then jumped by 33.53% to $50.4 million in 2019, then sank by 57.95% to $21.2 million in 2020, then soared by 545.51% to $136.9 million in 2021, then sank by 118.3% to -$25.1 million in 2022.
- According to Business Quant data, Beginning Cash Balance over the past three periods registered -$25.1 million, $60.4 million, and $136.9 million for Q4 2022, Q3 2022, and Q3 2021 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 161.55 Mn |
| Dec 31, 2025 | 161.55 Mn |
| Dec 31, 2024 | 62.96 Mn |
| Dec 31, 2024 | 62.96 Mn |
| Dec 31, 2023 | 71.32 Mn |
| Dec 31, 2023 | 71.32 Mn |
| Mar 31, 2023 | 60.45 Mn |
| Mar 31, 2023 | 60.45 Mn |
| Dec 31, 2022 | -25.06 Mn |
| Dec 31, 2022 | -25.06 Mn |
| Sep 30, 2022 | 60.45 Mn |
| Sep 30, 2022 | 60.45 Mn |
| Sep 30, 2021 | 136.88 Mn |
| Sep 30, 2021 | 136.88 Mn |
| Jun 30, 2021 | 78.90 Mn |
| Jun 30, 2021 | 78.90 Mn |
| Dec 31, 2020 | 21.21 Mn |
| Dec 31, 2020 | 21.21 Mn |
| Sep 30, 2020 | 129.33 Mn |
| Sep 30, 2020 | 129.33 Mn |